Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
Revive Therapeutics (OTCQB: RVVTF) has issued a clarification regarding its ongoing research study of Bucillamine as a potential nerve agent countermeasure. The study, conducted in partnership with Defence R&D Canada � Suffield Research Centre (DRDC), is investigating compounds that could mitigate nerve agent-induced brain injury.
The research is scheduled to continue through September 2025. Results will only be released with DRDC's explicit authorization. The company emphasized that any future research collaborations with DRDC would only be considered after the current study's completion and dependent on satisfactory results.
Revive Therapeutics (OTCQB: RVVTF) ha fornito un chiarimento riguardo al suo studio in corso su Bucillamina come possibile contromisura agli agenti nervini. Lo studio, condotto in collaborazione con il Defence R&D Canada � Suffield Research Centre (DRDC), sta esaminando composti in grado di ridurre i danni cerebrali causati dagli agenti nervini.
La ricerca è prevista fino a settembre 2025. I risultati verranno divulgati solo con l'esplicita autorizzazione del DRDC. L'azienda ha sottolineato che eventuali future collaborazioni di ricerca con il DRDC saranno valutate solo al termine dello studio attuale e in base ai risultati soddisfacenti ottenuti.
Revive Therapeutics (OTCQB: RVVTF) ha emitido una aclaración sobre su estudio en curso sobre Bucilamina como posible contramedida contra agentes nerviosos. El estudio, realizado en colaboración con el Defence R&D Canada � Suffield Research Centre (DRDC), investiga compuestos que podrían mitigar el daño cerebral inducido por agentes nerviosos.
La investigación está programada para continuar hasta septiembre de 2025. Los resultados solo se publicarán con la autorización explícita del DRDC. La empresa enfatizó que cualquier futura colaboración de investigación con el DRDC solo se considerará después de completar el estudio actual y dependiendo de resultados satisfactorios.
Revive Therapeutics (OTCQB: RVVTF)� 신경작용� 대� 가능성으로서의 부실라� 연구� 관� 진행 중인 연구� 대� 설명� 발표했습니다. � 연구� Defence R&D Canada � Suffield Research Centre (DRDC)와 협력하여 신경작용제로 인한 � 손상� 완화� � 있 화합물을 조사하고 있습니다.
연구� 2025� 9�까지 계속� 예정입니�. 결과� DRDC� 명시� 승인 없이� 공개되지 않습니다. 회사� 현재 연구 완료 � 만족스러� 결과� 따라 DRDC와� 향후 연구 협력� 검토될 것임� 강조했습니다.
Revive Therapeutics (OTCQB : RVVTF) a publié une clarification concernant son étude en cours sur la Bucillamine en tant que contre-mesure potentielle aux agents neurotoxiques. L'étude, menée en partenariat avec le Defence R&D Canada � Suffield Research Centre (DRDC), examine des composés susceptibles d'atténuer les lésions cérébrales induites par les agents neurotoxiques.
La recherche est prévue jusqu'en septembre 2025. Les résultats ne seront publiés qu'avec l'autorisation explicite du DRDC. La société a souligné que toute future collaboration de recherche avec le DRDC ne serait envisagée qu'après la fin de l'étude en cours et en fonction des résultats satisfaisants obtenus.
Revive Therapeutics (OTCQB: RVVTF) hat eine Klarstellung zu seiner laufenden Studie über Bucillamin als potenzielle Gegenmaßnahme gegen Nervengifte veröffentlicht. Die Studie, die in Zusammenarbeit mit dem Defence R&D Canada � Suffield Research Centre (DRDC) durchgeführt wird, untersucht Verbindungen, die Hirnschäden durch Nervengifte mindern könnten.
Die Forschung soll bis September 2025 fortgesetzt werden. Ergebnisse werden nur mit ausdrücklicher Genehmigung des DRDC veröffentlicht. Das Unternehmen betonte, dass zukünftige Forschungskooperationen mit dem DRDC erst nach Abschluss der aktuellen Studie und bei zufriedenstellenden Ergebnissen in Betracht gezogen werden.
- None.
- None.
TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive� or the “Company�) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada � Suffield Research Centre (“DRDC�), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.
The research study with Bucillamine is slated for continuation through September 2025, and its findings will be disseminated exclusively with the express authorization of the DRDC. The Company affirms that future research endeavours with DRDC have not been broached and would only be deliberated subsequent to the conclusion of the current research study and contingent upon the satisfactory nature of its results, warranting further investigation.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development efforts to take advantage of several regulatory incentives awarded by the FDA, such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. For more information, visit .
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
:
±ٱ:
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information� within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may�, “could�, “intend�, “expect�, “believe�, “will�, “projected�, “estimated� and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors� in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at .
